Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials.

Suh, Koung Jin; Lee, Ji Yun; Shin, Dong-Yeop; Koh, Youngil; Bang, Soo-Mee; Yoon, Sung-Soo; Park, Seonyang; Kim, Inho; Lee, Jeong-Ok
International journal of hematology
2017Apr ; 246 ( 4 ) :.
PMID : 28378056
ÀúÀÚ »ó¼¼Á¤º¸
Suh, Koung Jin -
Lee, Ji Yun -
Shin, Dong-Yeop -
Koh, Youngil -
Bang, Soo-Mee -
Yoon, Sung-Soo -
Park, Seonyang -
Kim, Inho -
Lee, Jeong-Ok -
ABSTRACT
We analyzed adverse events (AEs) in 201 chronic phase CML patients treated with nilotinib (n?=?120) or dasatinib (n?=?81) as first- or second-line therapy. The dasatinib group had significantly higher grade 3-4 AEs compared to the nilotinib group (22 vs. 54%, p?
Dasatinib; Discontinuation; Nilotinib; Pleural effusion; Toxicity
¸µÅ©

ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Å°¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
The dasatinib group had significantly higher grade 3-4 AEs compared to the nilotinib group (22 vs. 54%, p < 0.001), and had more frequent dose reduction, interruption, and discontinuation (p < 0.001, p = 0.004, and p = 0.006, respectively).
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆdz⵵(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
10.1007/s12185-017-2225-1
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå